secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001714899-25-000072
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Further analyses of DNL343 in ALS show no NfL treatment effect; extension discontinued
--------------------------------------------------------------------------------

- Further analyses of Regimen G DNL343 showed no treatment effect on neurofilament light (NfL) biomarker over 24-week double-blind period.
- A subset completing additional 28-week open-label extension also showed no NfL effect.
- On Jan 6, 2025, Denali announced study did not meet primary endpoint of slowing ALS progression.
- Key secondary endpoints also not statistically different; active treatment extension for Regimen G discontinued.
- DNL343 safe and well tolerated; data to be presented at future medical meeting; future development assessed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000072/0001714899-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000072/dnli-20250305.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer